Geometrical structure of an iron epilayer on Si (111) : an X-ray standing wave analysis

dépôt d'une copie effectué avec l'aimable autorisation de EDP SciencesThe structure of an iron film, deposited at low temperature (50 °C) upon a silicon (111) substrate, has been determined by means of X-ray Standing Wave experiments performed at LURE (Orsay, France). Experimental results are coherent with the model of an abrupt interface between the adsorbate and the surface : the first site of adsorption terminates the bulk silicon and a body-centred iron layer epitaxially grows on the substrate with a preferential growth orientation

Mise en place de l'insulinothérapie fonctionnelle au CHU de Reims : impact sur l'équilibre métabolique et la qualité de vie

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Prise en charge du pied diabétique : rôle du pharmacien d'officine

REIMS-BU Santé (514542104) / SudocSudocFranceF

Causes des amputations du pied diabétique. A propos de 63 cas

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Prise en charge de l'ostéite du pied chez le patient diabétique

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

A new experimental XRSW set up at LURE

Vol. 25, ISBN 88-7794-032-

The evaluation of off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale

International audienceBACKGROUND:Off-loading is essential for diabetic foot management, but remains understudied. The evaluation of Off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) trial aims to evaluate the efficacy of a new removable device "Orthèse Diabète" in the healing of diabetic foot.METHODS/DESIGN:ORTHODIAB is a French multi-centre randomized, open label trial, with a blinded end points evaluation by an adjudication committee according to the Prospective Randomized Open Blinded End-point. Main endpoints are adjudicated based on the analysis of diabetic foot photographs. Orthèse Diabète is a new removable off-loading orthosis (PROTEOR, France) allowing innovative functions including real-time evaluation of off-loading and estimation of patients' adherence. Diabetic patients with neuropathic plantar ulcer or amputation wounds (toes or transmetatarsal) are assigned to one of 2 parallel-groups: Orthèse Diabète or control group (any removable device) according to a central computer-based randomization. Study visits are scheduled for 6 months (days D7 and D14, and months M1, M2, M3, and M6). The primary endpoint is the proportion of patients whose principal ulcer is healed at M3. Secondary endpoints are: the proportion of patients whose principal ulcer is healed at M1, M2 and M6; the proportion of patients whose initial ulcers are all healed at M1, M2, M3, and M6; principal ulcer area reduction; time-related ulcer-free survival; development of new ulcers; new lower-extremity amputation; infectious complications; off-loading adherence; and patient satisfaction. The study protocol was approved by the French National Agency for Medicines and Health Products Safety, and by the ethics committee of Saint-Louis Hospital (Paris). Comprehensive study information including a Patient Information Sheet has been provided to each patient who must give written informed consent before enrolment. Monitoring, data management, and statistical analyses are providing by UMANIS Life Science (Paris), independently to the sponsor. Since 27/10/2013, 13 centres have agreed to participate in this study, 117 participants were included, and 70 have achieved the study schedules. The study completion is expected for the end of 2016, and the main results will be published in 2017.CONCLUSION:ORTHODIAB trial evaluates an innovating removable off-loading device, seeking to improve diabetic foot healing (ClinicalTrials.gov identifier: NCT01956162)

Comparaison des outils bibliographiques et bibliométriques Web of Science et Scopus : rapport du groupe de réflexion mis en place par la Bibliothèque Interuniversitaire de la Communauté française de Belgique (BICfB)

Depuis 2002, l'ensemble des membres de la BICfB souscrivent au Web of Science (WoS) de Thomson Reuters, plus précisément aux sous-bases Science Citation Index (SCI), Social Sciences Citation Index (SCCI) et Arts and Humanities Citation Index (A&HCI). Web of Science, partie du Web of Knowledge (WoK), est une base de données bibliographiques et d'analyse de citations renommée, au départ unique en son genre. Avec le Journal Citation Reports (JCR), elle est également beaucoup utilisée comme base de référence dans l'évaluation des chercheurs et de la recherche. En 2004, deux ressources concurrentes ont vu le jour. Il s'agit de Google Scholar (gratuit mais n'offrant pas autant de fonctionnalités) et de Scopus, un produit Elsevier. Aussi, lors de l'Assemblée générale de la BICfB du 4 mai 2010, les institutions ont décidé de constituer un groupe de réflexion interuniversitaire composé de membres issus des conseils ou administrations de la recherche, de bibliothèques et de représentants du F.R.S.-FNRS afin de comparer en profondeur ces outils. Ce rapport, présenté lors de l'AG du 7 juin 2011 de la BICfB, est le fruit du travail du groupe de réflexion